Laxxon Medical Appoints Matthew Cascio as Vice President and Head of Business Development to Drive Strategic Partnerships
Laxxon Medical has announced the appointment of Matthew Cascio as Vice President and Head of Business Development, strengthening the company’s leadership as it advances its pharmaceutical pipeline and expands opportunities for strategic collaboration. Cascio brings more than 20 years of experience in the global pharmaceutical industry, with expertise spanning corporate development, strategic licensing, research collaborations, and the commercial and scientific evaluation of pharmaceutical assets.
In his new role, Cascio will lead Laxxon Medical’s business development initiatives, focusing on identifying strategic partners, evaluating collaboration opportunities, and advancing the application of the company’s proprietary SPID® (Screen Printed Innovative Drugs) technology in pharmaceutical development. His appointment comes as Laxxon prepares to advance its LXM.2 and LXM.5 programs over the next two quarters, creating opportunities to engage pharmaceutical and biotechnology companies interested in differentiated drug formulations and innovative drug-delivery solutions.
Cascio joins Laxxon from Amneal Pharmaceuticals, where he most recently served as Senior Director of Corporate Development and Head of Specialty Business Development. Before joining Amneal, he spent more than a decade at Lundbeck in corporate business development and strategy positions, contributing to a broad range of transactions involving licensing agreements, mergers and acquisitions, asset acquisitions, equity investments, and research collaborations.
Throughout his career, Cascio has led or contributed to more than 60 completed transactions, building experience in evaluating pharmaceutical assets, structuring partnerships, negotiating strategic agreements, and supporting commercial development opportunities. His combination of scientific training and financial expertise is expected to support Laxxon’s efforts to establish new relationships, evaluate potential collaborations, and maximize the commercial opportunities associated with its drug-delivery platform.
The appointment reflects Laxxon Medical’s continued focus on strengthening its business development capabilities as the company works to translate its proprietary pharmaceutical technology into development programs and partnerships with industry participants.
Strengthening Laxxon Medical’s Business Development Strategy
Laxxon Medical’s appointment of Cascio represents a strategic investment in the company’s ability to identify and pursue growth opportunities across the pharmaceutical and biotechnology sectors. As drug developers increasingly explore formulation technologies that can improve the delivery, performance, and differentiation of existing and emerging therapies, partnerships between technology providers and pharmaceutical companies can play an important role in advancing product development.
In this environment, effective business development requires more than identifying prospective partners. Companies must assess the scientific rationale behind a technology, determine its suitability for specific pharmaceutical assets, evaluate commercial opportunities, and establish agreements that align the interests of all parties.
Cascio’s background in corporate development and pharmaceutical strategy is relevant to these activities. His experience across licensing, acquisitions, investments, and research collaborations provides a foundation for evaluating potential opportunities from both scientific and commercial perspectives.
At Laxxon, his responsibilities will include identifying pharmaceutical assets that could benefit from the company’s proprietary SPID® technology, exploring potential collaborations with pharmaceutical and biotechnology companies, and helping advance opportunities from initial evaluation to strategic agreement.
These activities may involve assessing the development potential of candidate products, identifying suitable commercial partners, evaluating the strategic value of different collaboration structures, and supporting negotiations designed to establish mutually beneficial relationships.
Helmut Kerschbaumer, CEO and Chairman of Laxxon Medical, highlighted the importance of Cascio’s experience as the company prepares for its next stage of development.
“Matthew brings a valuable combination of scientific insight, financial acumen, and pharmaceutical business development expertise that will be instrumental as Laxxon advances its pipeline and pursues strategic growth opportunities,” Kerschbaumer said.
He also emphasized the relevance of Cascio’s experience to the company’s upcoming programs and its efforts to establish strategic collaborations.
“As we prepare to advance our LXM.2 and LXM.5 programs over the next two quarters, his experience in asset evaluation, partnership structuring, and transaction execution will be critical to positioning these programs for strategic collaboration and maximizing their commercial potential.”
The company’s near-term priorities include preparing its pipeline programs for further advancement while evaluating how partnerships could support their development and commercialization. Cascio’s appointment is intended to strengthen the expertise available to execute that strategy.
Extensive Pharmaceutical Industry Experience
Cascio brings more than two decades of global pharmaceutical industry experience, including leadership and contributions across a range of corporate development and business development activities.
Most recently, he served as Senior Director of Corporate Development and Head of Specialty Business Development at Amneal Pharmaceuticals. His responsibilities in this area placed him within the broader strategic and commercial activities involved in evaluating pharmaceutical opportunities and identifying potential avenues for business growth.
Before his time at Amneal, Cascio spent more than ten years at Lundbeck, where he held corporate business development and strategy roles. During this period, he contributed to transactions involving multiple types of strategic arrangements, including licensing agreements, mergers and acquisitions, asset acquisitions, equity investments, and research collaborations.
These transaction categories represent different approaches to pharmaceutical business development. Licensing agreements can provide companies with rights to develop, manufacture, or commercialize products or technologies. Acquisitions can enable organizations to obtain assets, intellectual property, or businesses that complement their existing operations. Equity investments and research collaborations can also support the development of scientific programs and establish longer-term relationships between organizations.
Experience across these different structures can be valuable for a company such as Laxxon Medical, whose technology may be applicable to pharmaceutical assets owned or developed by other organizations.
For technology-driven pharmaceutical companies, selecting the appropriate partnership model can be an important component of a development strategy. Depending on the asset and its development stage, a collaboration may focus on research, formulation development, licensing, commercialization, or a combination of these activities.
Cascio’s record of leading or contributing to more than 60 completed transactions demonstrates the breadth of his experience in this environment. His background is expected to support Laxxon’s efforts to assess prospective opportunities, determine how its technology could complement partners’ development programs, and structure agreements that align scientific objectives with commercial considerations.
His appointment also reflects the importance of experienced transaction leadership when companies seek to expand the reach of proprietary technologies through external partnerships rather than relying exclusively on internal development.
Advancing the SPID® Drug-Delivery Platform
A central component of Laxxon Medical’s strategy is its proprietary SPID® technology, which is designed to enable precision-engineered pharmaceutical formulations, including controlled-release and combination products.
Drug formulation and delivery technologies can influence how an active pharmaceutical ingredient is incorporated into a medicine and released following administration. Depending on the formulation, these technologies may provide opportunities to modify drug-release characteristics, combine multiple active ingredients, or develop differentiated dosage forms.
Controlled-release formulations are designed to regulate the release of a drug over a defined period rather than delivering the active ingredient entirely at once. Such approaches can be relevant when developers seek to alter the timing or duration of drug release, although the potential benefits depend on the specific drug, formulation, route of administration, and clinical requirements.
Combination products can bring multiple therapeutic components together within a single formulation or dosage form. These products may offer development opportunities where combining treatments or coordinating their release characteristics is scientifically and clinically appropriate.
Laxxon’s SPID® platform is intended to support the development of precision-engineered formulations that may help pharmaceutical partners explore these possibilities.
For pharmaceutical companies, formulation technologies can offer another route to product differentiation. In some cases, developers may investigate alternative delivery approaches for existing active ingredients or explore ways to improve the practical characteristics of a medicine. However, any potential advantages must be demonstrated through appropriate development studies and, where applicable, clinical and regulatory evaluation.
Laxxon’s business development strategy will therefore involve identifying pharmaceutical assets for which SPID® technology may offer a relevant development opportunity.
Cascio’s role will include evaluating potential applications of the platform and developing relationships with organizations that may benefit from its capabilities. This work will require an understanding of the scientific characteristics of individual drug candidates as well as the commercial considerations that influence pharmaceutical development decisions.
The company’s objective is to establish collaborations that connect its formulation technology with pharmaceutical programs where the platform may offer a meaningful opportunity for differentiation.
LXM.2 and LXM.5 Programs Represent Near-Term Priorities
Laxxon Medical’s plans to advance its LXM.2 and LXM.5 programs over the next two quarters represent important priorities for the company’s development strategy.
According to the announcement, Cascio’s experience in asset evaluation, partnership structuring, and transaction execution will be particularly relevant as the company works to position these programs for strategic collaboration.
For pharmaceutical development companies, preparing a program for partnership typically involves assessing the underlying scientific rationale, reviewing available development data, identifying potential applications, and determining which organizations may have the capabilities or commercial interests to support further advancement.
Partnership discussions may also involve evaluating intellectual property considerations, development responsibilities, potential financing arrangements, and the allocation of commercial rights. The specific structure will depend on the characteristics of the program and the objectives of the parties involved.
Cascio’s background across multiple transaction types may help Laxxon evaluate different options for advancing its programs. These could include licensing arrangements, research partnerships, or other strategic agreements, depending on the scientific and commercial circumstances.
The company has not detailed the specific indications, development milestones, or anticipated commercial arrangements associated with LXM.2 and LXM.5 in the announcement. Nevertheless, their planned advancement over the next two quarters provides a defined near-term context for the appointment.
By strengthening its business development leadership ahead of these activities, Laxxon aims to improve its ability to engage prospective partners and evaluate opportunities that could support the programs’ progress.
Successful collaborations could potentially provide access to additional development expertise, resources, and commercial capabilities. They may also help connect Laxxon’s formulation technology with pharmaceutical portfolios that could benefit from differentiated drug-delivery approaches.
The eventual impact of these efforts will depend on the progress of the programs, the outcomes of partner evaluations, and the terms and execution of any agreements that may result.
Scientific Training and Financial Expertise
Cascio’s academic background combines financial education with advanced training in the life sciences.
He holds a Master of Business Administration in Finance from Fordham University’s Gabelli School of Business and a Master of Science in Cell and Molecular Biology from Fordham University. Earlier in his career, he conducted research at Johns Hopkins University, with findings published in Nature Cell Biology.
This combination of scientific and financial expertise is relevant to pharmaceutical business development, where decisions frequently require the integration of technical, clinical, regulatory, and commercial considerations.
Scientific training can help professionals evaluate the underlying biology of a therapeutic asset, understand research findings, and assess how a technology may fit within a development program. Financial and business training can support the evaluation of commercial potential, transaction structures, investment requirements, and strategic value.
In pharmaceutical corporate development, these perspectives often need to be considered together. A scientifically promising asset may still require a viable commercial strategy, while an attractive market opportunity must be supported by a credible development rationale.
Cascio’s experience across scientific research, corporate strategy, and pharmaceutical transactions provides a combination of capabilities that could support Laxxon’s efforts to identify and advance partnership opportunities.
His research background also provides context for his work evaluating pharmaceutical assets and technologies. Although the commercial development of a drug differs substantially from laboratory research, familiarity with scientific methods and published findings can help inform discussions about the evidence supporting a candidate or platform.
Expanding Pharmaceutical and Biotechnology Partnerships
Laxxon Medical’s appointment of Cascio underscores the company’s continued emphasis on building relationships with pharmaceutical and biotechnology organizations.
Strategic partnerships can be important for companies developing specialized drug-delivery technologies because the application of a platform may extend beyond a single internally developed product. Collaborations can create opportunities to apply the technology to additional pharmaceutical assets, evaluate new formulations, and explore commercial pathways with established industry participants.
For prospective partners, the value of a formulation platform depends on its suitability for a particular drug, the strength of the supporting evidence, the feasibility of manufacturing, regulatory considerations, and the potential to address a meaningful development or commercial need.
Business development teams play an important role in bringing these considerations together. They identify potential applications, assess strategic alignment, coordinate scientific and commercial evaluations, and negotiate agreements that define the responsibilities and rights of the participating organizations.
Under Cascio’s leadership, Laxxon intends to pursue these activities while advancing its pipeline and evaluating the broader potential of SPID® technology.
The company’s immediate focus on LXM.2 and LXM.5 provides an opportunity to align business development activities with specific pipeline priorities. At the same time, continued engagement with external pharmaceutical and biotechnology companies may help Laxxon explore additional applications for its technology.
The appointment does not itself establish any new licensing agreements or confirm commercial outcomes for the company’s programs. Rather, it strengthens the leadership structure intended to support future transactions and strategic relationships.
A Strategic Step in Laxxon’s Growth
Cascio’s appointment as Vice President and Head of Business Development marks a further step in Laxxon Medical’s efforts to expand its pharmaceutical development activities and build a broader network of strategic partners.
His more than 20 years of industry experience, including more than a decade at Lundbeck and his most recent role at Amneal Pharmaceuticals, bring substantial experience in corporate development, strategic licensing, asset evaluation, and transaction execution.
That experience will be applied to identifying opportunities for SPID® technology, strengthening relationships with pharmaceutical and biotechnology companies, and supporting the planned advancement of the LXM.2 and LXM.5 programs over the next two quarters.
As pharmaceutical developers continue to evaluate differentiated formulations and alternative drug-delivery strategies, Laxxon aims to position its proprietary platform as a potential resource for partners seeking new approaches to pharmaceutical development.
The company’s ability to convert these opportunities into meaningful collaborations will depend on the scientific and commercial suitability of individual programs, the strength of its supporting development evidence, and the successful negotiation and execution of future agreements.
With Cascio leading business development, Laxxon Medical is strengthening its capacity to pursue those opportunities while continuing to advance its pipeline and explore the potential applications of its precision-engineered drug-delivery technology.
About Laxxon Medical
Founded in 2017, Laxxon Medical is transforming pharmaceutical development through its proprietary SPID®-Technology, an advanced additive manufacturing platform for next-generation oral dosage forms. The technology offers unparalleled precision in sequential drug release and enables complex formulations, including peptide oral delivery, nanoparticle processing, and targeted drug delivery. SPID®-Technology provides distinct competitive advantages for pharmaceutical and biotech companies in lifecycle management and new drug development.
In addition to its industry partnerships, Laxxon uses SPID®-Technology to develop its own proprietary and generic therapies for metabolic disorders and central nervous system (CNS) conditions. Laxxon’s pipeline includes ongoing projects with pharmaceutical companies, biotech firms, and research universities, as well as 10 in-house Advanced Patented Generics products. Laxxon’s growing IP portfolio, together with licensed IP from Exentis Group, includes more than 150 patents and patent applications.